Disease response over time in eftoza plus venetoclax combination cohorts. Response per the International Working Group. Disease progression is assessed per European LeukemiaNet. Samples were assessed for DR4/DR5 expression via flow cytometry. DOR, duration of response; MR, morphologic relapse; PD, progressive disease; RD, resistant disease.